Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Gaylor

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Regulatory Toxicology and Pharmacology : RTP|April 1, 1992
Incidence of developmental defects at the no observed adverse effect level (NOAEL)D W Gaylor
Drug Metabolism Reviews|February 1, 1996
Risk estimation--an overview: disease risk estimation based upon animal bioassaysD W Gaylor
Toxicology and Industrial Health|December 1, 1988
Applicability of cancer risk assessment techniques to other toxic effectsD W Gaylor
Toxicology|August 30, 2000
The use of Haber's law in standard setting and risk assessmentD W Gaylor
Regulatory Toxicology and Pharmacology : RTP|December 1, 1996
Quantalization of continuous data for benchmark dose estimationD W Gaylor
Journal of Environmental Pathology and Toxicology|January 1, 1980
The ED01 study: summary and conclusionsD W Gaylor
Regulatory Toxicology and Pharmacology : RTP|October 1, 1989
Comparison of teratogenic and carcinogenic risksD W Gaylor
Regulatory Toxicology and Pharmacology : RTP|August 1, 1992
Relationship between the shape of dose-response curves and background tumor ratesD W Gaylor
Environmental Health Perspectives|February 1, 1989
Quantitative risk analysis for quantal reproductive and developmental effectsD W Gaylor
Drug Metabolism Reviews|April 25, 2000
New issues in cancer risk assessmentD W Gaylor
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Regulatory Toxicology and Pharmacology : RTP|April 1, 1992
Incidence of developmental defects at the no observed adverse effect level (NOAEL)D W Gaylor
Drug Metabolism Reviews|February 1, 1996
Risk estimation--an overview: disease risk estimation based upon animal bioassaysD W Gaylor
Toxicology and Industrial Health|December 1, 1988
Applicability of cancer risk assessment techniques to other toxic effectsD W Gaylor
Toxicology|August 30, 2000
The use of Haber's law in standard setting and risk assessmentD W Gaylor
Regulatory Toxicology and Pharmacology : RTP|December 1, 1996
Quantalization of continuous data for benchmark dose estimationD W Gaylor
Journal of Environmental Pathology and Toxicology|January 1, 1980
The ED01 study: summary and conclusionsD W Gaylor
Regulatory Toxicology and Pharmacology : RTP|October 1, 1989
Comparison of teratogenic and carcinogenic risksD W Gaylor
Regulatory Toxicology and Pharmacology : RTP|August 1, 1992
Relationship between the shape of dose-response curves and background tumor ratesD W Gaylor
Environmental Health Perspectives|February 1, 1989
Quantitative risk analysis for quantal reproductive and developmental effectsD W Gaylor
Drug Metabolism Reviews|April 25, 2000
New issues in cancer risk assessmentD W Gaylor
Pageof 12